SMN1 and proximal spinal muscular atrophy: The recently approved drugs for SMA, the antisense oligonucleotide Nusinersen and the gene therapy with AAV9-SMN1 [22, 46], represent a remarkable turning point for SMA therapy, with promising and exciting results.